Results 161 to 170 of about 7,656 (201)

Engineered retargeting to overcome systemic delivery challenges in oncolytic adenoviral therapy. [PDF]

Mol Ther Oncol
Leparc L, Wakimoto H.
europepmc   +1 more source

Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment. [PDF]

Antibodies (Basel)
Giannoni P, Pietra G, Izzo O, Fugazza G, Benelli R, Poggi A, Krampera M, Utzeri C, Marchese M, Musso M, Visconti P, de Totero D.   +11 more
europepmc   +1 more source

Bacterial exotoxins in medicine: potential value and perspectives. [PDF]

Int J Med Sci
Xiao Y, Yan Z, Ren F, Tan Y.
europepmc   +1 more source

Enhanced Antitumor Efficacy of a Combination of Immunotoxin and Photosensitizer Under Illumination in Xenograft Mice. [PDF]

Biomedicines
Hamakubo S, Komatsu N, Kosai A, Kuroda M, Sawada M, Shimizu R, Ohashi R, Suenaga H, Hamakubo T, Abe T.   +9 more
europepmc   +1 more source

Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches. [PDF]

Antibodies (Basel)
Godugu D, Gattu K, Suri P, Daartey AB, Jadhav K, Rojekar S.   +5 more
europepmc   +1 more source

Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. [PDF]

Ther Adv Med Oncol
Izzo D, Ascione L, Guidi L, Marsicano RM, Koukoutzeli C, Trapani D, Curigliano G.   +6 more
europepmc   +1 more source

A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy. [PDF]

Acta Pharm Sin B
Xi X, Wang Y, An G, Feng S, Zhu Q, Wu Z, Chen J, Zuo Z, Wang Q, Wang MW, Gu Y.   +10 more
europepmc   +1 more source

Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli. [PDF]

AMB Express
Mani S, Arab B, Akbari V, Chou CP.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CLL immunotoxins

Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire   +2 more sources

Recombinant immunotoxins

Breast Cancer Research and Treatment, 1996
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan, L H, Pai, U, Brinkmann, D, FitzGerald   +3 more
openaire   +2 more sources